The Study On The Relationship Between Cruor-fibrinolysis System And The HuiZhuoTanZu Syndrome Of Coronary Heart Disease

Objective:The aim of this study is to investigate the plasma level of Fibrinopeptide A (FPA) and Thrombin Activatable Fibrinolysis Inhibitor (TAFI), so as to explore the relationship between CHD HuiZhuoTanzhu Syndrome and endothelium dysfunction, provide the microcosmic objective basis for working out the diagnose standard for the coronary heart disease HuiZhuoTanZu Syndrome, in order to make its diagnose tend being externalization Methods:A total of 170 samples were obtained Medical University, including 88 cases of CHD huizhuotanzu syndrome and 82 cases of CHD non-huizhuotanzu syndrome,80 cases of normal controls, then observe and analyses the general data and the plasma level of FPA,TAFI among three groups. Results:1) Comparison of plasma FPA:Compared with normal controls, the lever of FPA of CHD HuiZhuoTanzhu Syndrome group and non- HuiZhuoTanzhu Syndrome group are significantly higher, the difference is statistically significant (P<0.01);between CHD HuiZhuoTanzhu Syndrome group and the non- HuiZhuoTanzhu Syndrome group, there is a significant difference in the lever of FPA (P<0.05).2) Plasma TAFI level in comparison:the lever of TAFI in CHD HuiZhuoTanzhu Syndrome group and non-HuiZhuoTanzhu Syndrome group are higher than healthy control group, the difference is significant (P<0.01), and the lever of TAFI in CHD HuiZhuoTanzhu Syndrome group is higher than non-HuiZhuoTanzhu Syndrome group (P<0.05). Conclusion:The Pathological basis of CHD HuiZhuoTanZu syndrome is related with the blood high pour-point state, there are more anomalies in Blood coagulation-fibrinolysis system function between the CHD HuiZhuoTanZu syndrome and non-HuiZhuoTanZu syndrome. The increasing contents of FPA, TAFI can help us to differentiate the CHD HuiZhuoTanZu syndrome and non-HuiZhuoTanZu syndrome.